📇 Rhumatologue · LA ROCHE SUR YON CEDEX 9 · (85) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Délais de RDV courts dans la région
97.1 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CHD SITE LA ROCHE SUR YON
LES OUDAIRIES BD STEPHANE MOREAU, 85925 LA ROCHE SUR YON CEDEX 9
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2009
AbstractBecause macrophages play a key role on host defense, visualization of the migration of these cells is of high relevance for both diagnostic purposes and the evaluation of therapeutic interventions. The present article addresses the use of iron oxide and gadolinium‐based particles for the noninvasivein vivodetection of macrophage infiltration into inflamed areas by magnetic resonance imaging (MRI). A general introduction on the functions and general characteristics of macrophages is followed by a discussion of some of the agents and acquisition schemes currently used to track the cellsin vivo. Attention is then devoted to preclinical and clinical applications in the following disease areas: atherosclerosis and myocardial infarction, stroke, multiple sclerosis, rheumatoid arthritis, and kidney transplantation Copyright © 2009 John Wiley & Sons, Inc.This article is categorized under:Diagnostic Tools > In Vivo Nanodiagnostics and Imaging
Journal of geriatric oncology · 2021
Journal of oncology · 2021
Objective. Anti-PD-1 has dramatically improved the survival of patients with advanced melanoma. However, there is a lack of data on maintenance of the response after treatment discontinuation. We aimed to evaluate the progression-free survival (PFS) of patients with metastatic melanoma after anti-PD-1 interruption for objective response (OR) or limiting toxicity during clinical trials. Methods. All patients with advanced melanoma who stopped single-agent anti-PD-1 antibodies for objective response or toxicity were included between April 2014 and January 2019 in our institution (data cut-off, September 10th, 2019). Clinical and biological factors associated with relapse were studied. Results. The median follow-up after introduction of treatment was 36.5 months [4.6–62.4], and the median follow-up after discontinuation of treatment was 15.7 months (2.5–45.1). Out of 65 patients, 28 patients stopped immunotherapy for limiting adverse effects (AEs) (43.1%), 25 for complete response (CR) (38.4%), and 12 for partial response (PR) or long-term stable disease (SD) (18.5%). Twelve patients relapsed (18.5%) after a median time of 9 months [1.9–40.9 months]. Seven relapsed after discontinuation for AEs, 3 after discontinuation for CR, and 2 after discontinuation for PR/SD. The median PFS after therapy discontinuation was not reached. No statistical association was found between recurrence and age, sex, increased LDH, BRAF status, presence of brain metastases, previous treatments, radiotherapy, or time on anti-PD-1 treatment. Conclusion. This cohort shows a global recurrence rate of 18.5% and confirms a long-lasting response after anti-PD-1 cessation regardless of the cause of discontinuation.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Journal of geriatric oncology · 2021 · Letter
Valentin J, Gérard E, Ferte T, Prey S, et al.
Journal of oncology · 2021 · Journal Article
Valentin J, Ferté T, Dorizy-Vuong V, Dousset L, et al.
Journal of geriatric oncology · 2021 · Letter
Valentin J, Gérard E, Ferte T, Prey S, et al.
Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2009 · Journal Article
Beckmann N, Cannet C, Babin AL, Blé FX, et al.
Journal of geriatric oncology · 2021 · Letter
Valentin J, Gérard E, Ferte T, Prey S, et al.
Journal de radiologie · 1999 · Evaluation Study
Berger O, Dousset V, Delmer O, Pointillart V, et al.